In another inside trade, Mostafa Adam S., Chief Financial Officer of X4 Pharmaceuticals Inc (NASDAQ:XFOR) sold 230,645 shares of the firm on Nov 01 for a total worth of $0.17 million at a price of $0.73. Ragan Paula, the President and CEO at X4 Pharmaceuticals Inc (XFOR) has sold 39,906 shares of firm on Nov 03 at a price of $0.90 against the total amount of $35915.0. Currently, 25.06 percent of X4 Pharmaceuticals Inc shares are owned by insiders, and 53.43 percent are held by financial institutions. XFOR stock is trading at a margin of -2.14%, -19.19% and -38.08% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.Īlmost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Despite the fact that the share price decreased -49.35% in the last 6 months and -51.15% was subtracted to its value over the previous 3 months. The firm’s stock price fluctuated 12.71% within the last five trades and -12.94% within the last 30 trades, which was a significant change from the beginning of this year. The stock price fluctuated between $0.8006 and $0.90 throughout the trading session with the volume trading being 2608315 shares, which represented a significant variation when compared to the three months average volume of 2.05 million shares. The share price of X4 Pharmaceuticals Inc (NASDAQ:XFOR) dipped -12.70% to close Monday’s market session at $0.83, lower as compared to yesterday’s close. The latest trade, Performances and Moving Averages give us the following Picture The rating was released on August 30, 2023, according to finviz. Riley Securities raised the price target for the X4 Pharmaceuticals Inc (NASDAQ:XFOR) stock to “a Buy”.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |